Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Superinvestors holding IMVT, Q2 2026
1 superinvestor reports holding Immunovant, Inc. on Form 13F, worth $3.60M in total. Weight is Immunovant, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Greenlight CapitalDavid Einhorn | 0.1% | 93,520 | $3.60M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of IMVT each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2026
1 superinvestor holding at quarter end
Q2 2025
0 superinvestors holding at quarter end
- Sold out
- Viking Global Investors
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−20.8%)
Q4 2024
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−39.4%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+28.3%)
Q1 2024
1 superinvestor holding at quarter end
- New
- Viking Global Investors
- Sold out
- Soros Fund Management
Q4 2023
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+86.7%)
Q3 2023
1 superinvestor holding at quarter end